Neoadjuvant Therapy Fundamental in Triple-Negative and HER2-Positive Breast Cancer

According to a recently presented study at the 15th St. Gallen International Breast Cancer Conference held in Vienna, Austria, the use of neoadjuvant therapy revolves around achieving a pathological complete response to surgery, which has been associated with improved outcomes.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.